Highlights Nanobiotix

Equities

NANO

FR0011341205

Market Closed - Euronext Paris Other stock markets 11:35:18 2024-04-26 am EDT			5-day change	1st Jan Change
5.45 ^EUR	+0.93%		+3.81%	-17.92%

Apr. 25	Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024
Apr. 24	Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
Nanobiotix completes escalation portion of 2020-0123 study	Apr. 03	CF
Nanobiotix Completes Dose Escalation Segment of Phase 1 Study Targeting Non-Small Cell Lung Cancer	Apr. 02	MT
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommends Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation	Apr. 02	CI
Nanobiotix: targets achieved for NANORAY-312	Jan. 30	CF
Nanobiotix Gets $20 Million Milestone Payment from Janssen	Jan. 30	MT
Nanobiotix: transfer of NBTXR3 rights in Asia	Dec. 27	CF
Nanobiotix Partner Transfers Asian Commercialization Rights for Oncology Therapy to Johnson & Johnson Unit	Dec. 27	MT
Nanobiotix Closes Issuance of Additional Shares to Johnson & Johnson Innovation – JJDC	Dec. 05	MT
Johnson & Johnson Discloses Stake in Nanobiotix	Nov. 17	MT
Nanobiotix S.A. Announces Updated Preliminary Results from Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis from Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023	23-10-23	CI
Nanobiotix S.A. Announces the Presentation of the Final Efficacy Analysis from Phase 1 Cohort Expansion Evaluating Nbtxr3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Months	23-10-04	CI
Nanobiotix S.A. Announces New Clinical Data from Phase 1 Study Evaluating Radiotherapy-Activated Nbtxr3 for Patients with Pancreatic Ductal Adenocarcinoma	23-09-28	CI
Nanobiotix S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
Nanobiotix Finalizes Licensing Deal for Radioenhancer NBTXR3 with Janssen	23-08-16	MT
NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3	23-08-15	CI
Tech spreads out	23-07-21
Nanobiotix S.A. Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers	23-07-19	CI
Nanobiotix Shares Surge Amid $60 Million Partnership With Janssen	23-07-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Nanobiotix

Equities

NANO

FR0011341205

Highlights

Filters